“ Results from ZUMA-1 Cohort 4 demonstrate that early steroid intervention has the potential to reduce the rate of severe CRS and neurologic events while appearing to maintain comparably impressive ...

A multicenter retrospective study that evaluated the efficacy and safety of chimeric antigen receptor (CAR) T-cell treatment, axicabtagene ciloleucel (axi-cel; Yescarta), in a real-world setting found ...

-- Unparalleled 44 Percent Estimated Four-Year Overall Survival Rate Among Refractory Large B-cell Lymphoma Patients After a Single Infusion of Yescarta -- -- Findings Support Yescarta as the First ...

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017. A much-anticipated session on the second day of the 59th Annual Meeting and Exposition ...

ATLANTA--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory ...

Please provide your email address to receive an email when new articles are posted on . Treatment with the anti-PD-L1 antibody atezolizumab after the chimeric antigen receptor T-cell therapy ...

Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate. This is an ASCO Meeting Abstract from ...